Lesson plan
Vorolanib
Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed. Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration. and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally. It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).
Article summary
Vorolanib is a drug with antiangiogenic and antineoplastic activities. In 2023, vorolanib was approved for use in China. It is used in combination with everolimus for the treatment of advanced renal cell carcinoma in patients who have previously received tyrosine kinase inhibitor treatment but failed. Vorolanib is also being evaluated for the treatment of neovascular age‑related macular degeneration. and its azidated and chlorinated version, termed EYE1118, is designed to be targeted to the eye by natural light to reduce retinal and choroidal neovascularization locally. It is a dual inhibitor that targets both vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).
Key claims
No claims recorded.
Discussion questions
- Summarise the article in your own words. Which single claim would you verify first, and why?
- Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
- If two sources disagreed about one of these facts, what would you need in order to trust one over the other?
Bibliography
No sources recorded.
Key claims and bibliography are generated from the same tracked claims and sources as the article page.